Credit Suisse analyst Phil Winslow maintains Teradata (NYSE:TDC) with a Underperform and raises the price target from $34 to $35.
AstraZeneca Unit Alexion Said Aims to Advance NMOSD Treatment Landscape with Exceptional Ultomiris Efficacy data at ECTRIMS 2022
Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, 26 to 28 October 2022.
